Antidepressant use in demented elderly subjects: Current data;Utilisation des antidépresseurs chez les sujets âgés déments : données actuelles

Revue de Medecine Interne

Volumn 30, Issue 11, 2009, Pages 947-954

  Belicard Pernot C ^a   Manckoundia, P ^a,b   Ponavoy, E ^c   Rouaud, O ^c   Pfitzenmeyer, P ^a,b  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c HÔPITAL DU BOCAGE   (France)

Author keywords

Alzheimer disease; Antidepressant; Behavioral disturbances; Dementia; Elderly

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DIVARIUS; DOXEPIN; DULOXETINE; EFFEXOR LP; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE MALEATE; HALOPERIDOL; IMIPRAMINE; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; NORSET; PAROXETINE; PERPHENAZINE; PIRACETAM; PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIPRALEX; TIANEPTINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; CLINICAL TRIAL; DEMENTIA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG UTILIZATION; HUMAN; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; RISK BENEFIT ANALYSIS; SHORT SURVEY; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

AGED; ANTIDEPRESSIVE AGENTS; DEMENTIA; DEPRESSION; HUMANS;

EID: 72049107746     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2009.01.023     Document Type: Short Survey

References (74)

1. Clément J.P., and Léger J.M. Clinique et épidémiologie de la dépression du sujet âgé. In: Lempérière T. (Ed). Les dépressions du sujet âgé (1996), Acanthe-Masson, Paris 19-26
2. Helmer C., Montagnier D., and Pérès K. Epidémiologie descriptive, facteurs de risque, étiologie de la dépression du sujet âgé. Psychol Neuropsychiatr Vieil 2 (2004) S7-S12
3. Pancrazi M.P. La dépression dans la maladie d'Alzheimer. Rev Geriatr 27 (2002) 202-206
4. Thomas P., and Hazif-Thomas C. Dépression, présentation clinique et diagnostic chez la personne âgée. Rev Geriatr 28 (2003) 247-258
5. Paterniti S.S., Verdier-Taillefer M.H., Dufouil C., and Alperovitch A. Depressive symptoms and cognitive decline in elderly people. Br J Psychiatry 181 (2002) 406-410
6. Munro C.A., Brandt J., Sheppard J.E., Steele C., Samus Q.M., Steinberg M., et al. Cognitive response to pharmalogical treatment for depression in Alzheimer Disease: secondary outcomes from the depression in Alzheimer's Disease Study (DIADS). Am J Geriatr Psychiatry 12 (2004) 491-498
7. Pancrazi M.P., and Metais P. Maladie d'Alzheimer, traitement des troubles psychologiques et comportementaux. Presse Med 34 (2005) 667-672
8. Alexopoulos GS, Jeste DV, Chung H, Carpenter D, Ross R, Docherty JP. The expert consensus guidelines series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary. Postgrad Med 2005:6-22 [special issue].
9. Caballero J., Hitchcock M., Beversdorf D., Scharre D., and Nahata M. Long-term effects of antidepressants on cognition in patients with Alzheimer's disease. J Clin Pharm Ther 31 (2006) 593-598
10. Sink K.M., Holden K.F., and Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 293 (2005) 596-608
11. Feinberg T., and Goodman B. Affective illness, dementia, and pseudodementia. J Clin Psychiatry 45 (1984) 99-103
12. Baldwinn R.C., and O'Brien J. Vascular basis of late-onset depressive disorder. Br J Psychiatry 180 (2002) 157-160
13. Alexopoulos G.S., Meyers B.S., Young R.C., Mattis S., and Kakuma T. The course of geriatric depression with "reversible dementia": a controlled study. Am J Psychiatry 150 (1993) 1693-1699
14. Wilson R.S., Barnes L.L., Mendes de Leon C.F., Aggarwal N.T., Schneider J.S., Bach J., et al. Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology 59 (2002) 364-370
15. Lyketsos C.G. Neuropsychiatric symptoms (behavioral and psychological symptoms of dementia) and the development of dementia treatments. Int Psychogeriatr 19 (2007) 409-420
16. Merriam A.E., Aronson M.K., Gaston P., Wey S.L., and Katz I. The psychiatric symptoms of Alzheimer's disease. J Am Geriatr Soc 36 (1988) 7-12
17. Thomas P., Clément J.P., Hazif-Thomas C., and Léger J.M. Family, Alzheimer's disease and negative symptoms. Int J Geriatr Psychiatry 16 (2001) 192-202
18. Cummings J.L. Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis. Neurobiol Aging 21 (2000) 845-861
19. Lyketsos C.G., and Olin J. Depression in Alzheimer's disease in the U.S. population: prevalence estimates using the 2000 Census. Arch Neurol 60 (2003) 1119-1122
20. Ritchie K., Touchon J., and Ledésert B. Progressive disability in senile dementia is accelerated in the presence of depression. Int J Geriatr Psychiatry 13 (1998) 459-461
21. Ballard C., Lowery K., Powell I., O'Brien J., and James I. Impact of behavioral and psychological symptoms of dementia on caregivers. Int Psychogeriatr 12 (2000) 93-105
22. Sachs-Ericsson N, Blazer DG. Depression in late life: etiology, diagnosis and treatment. In: Pathy MSJ, Sinclair AJ, Morley JE, editors. Principles and practice of geriatric medicine, 4th edition, vol. 2. Hoboken: John Wiley ; Sons Inc.; 2006. p. 1173-83.
23. Kirby D., Harrigan S., and Ames D. Hyponatremia in elderly psychiatric patients treated with selective serotonin reuptake inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit. Int J Geriatr Psychiatry 17 (2002) 231-237
24. Rigler S.K., Webb M.J., Redford L., Brown E.F., Zhou J., and Wallace D. Weight outcomes among antidepressant users in nursing facilities. J Am Geriatr Soc 49 (2001) 49-55
25. Remigereau J., Postec C., and Pautas E. Inhibiteurs de la recapture de la sérotonine et déminéralisation osseuse chez les femmes âgées. Rev Geriatr 33 (2008) 63-65
26. Lang P.O., Hasso Y., Hilleret H., and Vogt-Ferrier N. Syndrome sérotoninergique consécutif à l'association d'escitalopram et de cyclosporine chez une patiente de 84 ans. Rev Med Interne 29 (2008) 583-586
27. Haney E.M., Chan B.K., Diem S.J., Ensrud K.E., Cauley J.A., Barrett-Connor E., et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 167 (2007) 1246-1251
28. Kelsey J.E., and Nemeroff C.B. Selective serotonine reuptake inhibitors. In: Saddock B.J., and Saddock V.A. (Eds). Comprehensive textbook of psychiatry vol. 2 (2000), Lippincott Williams and Wilkins, Philadelphia 2432-2444
29. Vandel P. Antidepressant drugs in the elderly - role of the cytochrome P450 2D6. World J Biol Psychiatry 4 (2003) 74-80
30. Solai L.K., Mulsant B.H., and Pollock B.G. Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drugs Aging 18 (2001) 355-368
31. Clément J.P. Moclobémide et dépression du sujet âgé. Neurol Psychiatr Geriatr 3 (2003) 42-47
32. ®). Rev Fr Geriatr Gerontol 13 (2006) 514-523
33. Hazif-Thomas C., Thomas P., and Guillibert E. La démotivation de la personne âgée démente. De la reprise à la repetition. Ann Med Psychol 153 (1995) 261-268
34. Reid I.C., and Stewart C.A. How antidepressant work: new perspectives on the pathophysiology of depressive disorder. Br J Psychiatry 178 (2001) 299-303
35. Fuchs E., Czéh B., Michaelis T., de Biurrun G., Watanabe T., and Frahm J. Synaptic plasticity and tianeptine: structural regulation. Eur Psychiatry 17 (2002) 311-317
36. Reding M., Young R., and Diponte P. Amitriptyline in Alzheimer's disease. Neurology 33 (1983) 522-523
37. Taragano F.E., Lyketsos C.G., Mangone C.A., Allegri R.F., and Comesana-Diaz E. A double-blind, randomized, fixed-dose trial of fluoxétine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 38 (1997) 246-252
38. Reifler B.V., Teri L., Raskind M., Veith R., Barnes R., White E., et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry 146 (1989) 45-49
39. Katona C.L., Hunter B.N., and Bray J. A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry 13 (1998) 100-108
40. Petracca G., Teson A., Chemerinski E., Leiguarda R., and Starkstein S.E. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 8 (1996) 270-275
41. Reifler B.V., Larson E., Teri L., and Poulsen M. Dementia of the Alzheimer's type and depression. J Am Geriatr Soc 34 (1986) 855-859
42. Olafsson K., Jorgensen S., Jensen H.V., Bille A., Arup P., and Andersen J. Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study. Acta Psychiatr Scand 85 (1992) 453-456
43. Lebert F., Pasquier F., and Petit H. Behavioral effects of fluoxetine in dementia of Alzheimer's type. Int J Geriatr Psychiatry 9 (1994) 590-591
44. Auchus A.P., and Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 9 (1997) 591-593
45. Petracca G.M., Chemerinski E., and Starkstein S.E. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr 13 (2001) 233-240
46. Nyth A.L., and Gottfries C.G. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry 157 (1990) 894-901
47. Nyth A.L., Gottfries C.G., Lyby K., Smedegaard-Andersen L., Gylding-Sabroe J., Kristensen M., et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 86 (1992) 138-145
48. Pollock B.G., Mulsant B.H., Rosen J., Sweet R.A., Mazumdar S., Bharucha A., et al. Comparison of Citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 159 (2002) 460-465
49. Scharre D.W., Davis R.A., Warner J.L., Chang S.I., and Beversdorf D.Q. A pilot open-label trial of citalopram for restless activity and aberrant motor behaviors in Alzheimer disease. Am J Geriatr Psychiatry 11 (2003) 687-691
50. Pollock B.G., Mulsant B.H., Rosen J., Mazumdar S., Blakesley R.E., Houck P.R., et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 15 (2007) 942-952
51. Lyketsos C.G., Sheppard J.M., Steele C.D., Kopunek S., Steinberg M., Baker A.S., et al. Randomized, placebo-controlled, double-blind clinical trial of Sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Am J Psychiatry 157 (2000) 1686-1689
52. Lyketsos C.G., DelCampo L., Steinberg M., Miles Q., Steele C.D., Munro C., et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 60 (2003) 737-746
53. Devanand D.P., Pelton G.H., Marston K., Camacho Y., Roose S.P., Stern Y., et al. Sertraline treatment of elderly patients with depression and cognitive impairment. Int J Geriatr Psychiatry 18 (2003) 123-130
54. Moretti R., Torre P., Antonello R.M., Cazzato G., and Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. Eur Neurol 49 (2003) 13-19
55. Deakin J.B., Rahman S., Nestor P.J., Hodges J.R., and Sahakian B.J. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology 172 (2004) 400-408
56. de Vasconcelos Cunha U.G., Lopes Rocha F., Avila de Melo R., Alves Valle E., de Souza Neto J.J., Mendes Brega R., et al. A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia. Dement Geriatr Cogn Disord 24 (2007) 36-41
57. Mizukami K., Tanaka Y., and Asada T. Efficacy of milnacipran on the depressive state in patients with Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 1342-1346
58. Postma J.U., and Vranesic D. Moclobemide in the treatment of depression in demented geriatric patients. Acta Ther 11 (1985) 1-4
59. Pancheri P., Delle-Chiaie R., Donnini M., Seripa S., Gambino C., Vicario E., et al. Effects of moclobemide on depressive symptoms and cognitive performance in a geriatric population: a controlled comparative study versus. imipramine. Clin Neuropharmacol 17 (1994) S58-73
60. Roth M., Mountjoy C.Q., and Amrein R. Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br J Psychiatry 168 (1996) 149-157
61. Adler G., Teufel M., and Drach L.M. Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide. Int J Geriatr Psychiatry 18 (2003) 653-655
62. Karlson I., Godderis J., Augusto De Mendonça Lima C., Nygaard H., Simanyi M., Taal M., et al. A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia. Int J Geriatr Psychiatry 15 (2000) 295-305
63. Raji M.A., and Brady S.R. Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. Ann Pharmacother 35 (2001) 1024-1027
64. Lebert F., Pasquier F., and Petit H. Behavioral effects of trazodone in Alzheimer's disease. J Clin Psychiatry 55 (1994) 536-538
65. Teri L., Logsdon R.G., Peskind E., Raskind M., Weiner M.F., Tractenberg R.E., et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 55 (2000) 1271-1278
66. Lebert F., Stekke W., Hasenbroekx C., and Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord 17 (2004) 355-359
67. Finkel S.I., Mintzer J.E., Dysken M., Krishnan K.R., Burt T., and McRae T. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry 19 (2004) 9-18
68. Lawlor B.A., Radcliffe J., Molchan S.E., Martinez R.A., Hill J.L., and Sunderland T. A pilot placebo-controlled study of trazodone and buspirone in Alzheimer's disease. Int J Geriatr Psychiatry 9 (1994) 55-59
69. López-Pousa S., Garre-Olmo J., Vilalta-Franch J., Turon-Estrada A., and Pericot-Niegra I. Trazodone for Alzheimer's disease: a naturalistic follow-up study. Arch Gerontol Geriatr 47 (2008) 207-215
70. Thompson S., Herrmann N., Rapoport M.J., and Lanctôt K.L. Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis. Can J Psychiatry 52 (2007) 248-255
71. Sink K.M., Holden K.F., and Yalffe K. Pharmalogical treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 293 (2005) 596-608
72. Pancrazi M.P., Benoit M., Brocker P., Clement J.P., Cnockaert X., Hinault P., et al. Traitement pharmacologique des SCPD. Rev Fr Geriatr Gerontol 10 (2003) 452-458
73. Martinon-Torres G, Fioravanti M, Grimley EJ. Trazodone for agitation in dementia. Cochrane Database Syst Rev 2004;18:CD004990.
74. HAS. Recommandations professionnelles. Diagnostic et prise en charge de la maladie d'Alzheimer et des maladies apparentées. Disponible sur www.has-sante.fr [consulté en 2008].